iBio (IBIO) Net Income towards Common Stockholders (2010 - 2026)
iBio (IBIO) posted quarterly Net Income towards Common Stockholders of -$7.7 million for Q1 2026, down 59.02% year-over-year from -$18.9 million in Q1 2025, and up 14.04% quarter-over-quarter from -$9.0 million in Q4 2025.
iBio (IBIO) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$7.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 59.02% year-over-year to -$7.7 million; the TTM figure through Mar 2026 stood at -$27.2 million (down 53.45% YoY), while the FY2025 annual figure was -$81.6 million, down 761.76% from the prior year.
- Net Income towards Common Stockholders climbed to -$7.7 million in Q1 2026 per IBIO's latest filing, from -$9.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$537000.0 in Q1 2024 and bottomed at -$23.0 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$6.6 million across 5 years, with a median of -$4.8 million in 2025.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 33539.22% — and 2023, when it soared 93.54%.
- iBio's Net Income towards Common Stockholders stood at -$23.0 million in 2022, then surged by 83.81% to -$3.7 million in 2023, then decreased by 17.22% to -$4.4 million in 2024, then sank by 106.07% to -$9.0 million in 2025, then gained by 14.04% to -$7.7 million in 2026.
- Business Quant data shows IBIO's Net Income towards Common Stockholders at -$7.7 million in Q1 2026, -$9.0 million in Q4 2025, and -$5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | -7.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.73 Mn |
| Dec 31, 2025 | -8.99 Mn |
| Sep 30, 2025 | -5.67 Mn |
| Jun 30, 2025 | -4.84 Mn |
| Mar 31, 2025 | -4.86 Mn |
| Dec 31, 2024 | -4.36 Mn |
| Sep 30, 2024 | -3.99 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Mar 31, 2024 | -537,000.00 |
| Dec 31, 2023 | -3.72 Mn |
| Sep 30, 2023 | -672,000.00 |
| Jun 30, 2023 | -1.10 Mn |
| Mar 31, 2023 | -1.02 Mn |
| Dec 31, 2022 | -22.99 Mn |
| Sep 30, 2022 | -7.54 Mn |
| Jun 30, 2022 | -17.05 Mn |
| Mar 31, 2022 | -12.39 Mn |
| Dec 31, 2021 | -11.94 Mn |
| Sep 30, 2021 | -5.25 Mn |
| Jun 30, 2021 | 51,000.00 |